{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T04:35:41Z","timestamp":1764304541803,"version":"3.37.3"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":790,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014487","name":"Clovis Oncology, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014487","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Treatment options for women with recurrent ovarian cancer who have received two or more prior lines of chemotherapy have recently expanded with the U.S. Food and Drug Administration (FDA) and European Commission (EC) approvals of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib. As more oncologists begin to use rucaparib and other PARP inhibitors as part of routine clinical practice, awareness of possible side effects and how to adequately manage toxicities is crucial. In this review, we summarize the safety and tolerability of rucaparib reported in an integrated safety analysis that supported the FDA's initial approval of rucaparib in the treatment setting. Additionally, drawing on clinical data and our personal experience with rucaparib, we provide our recommendations on the management of common side effects observed with rucaparib, including anemia, blood creatinine elevations, alanine aminotransferase and aspartate aminotransferase elevations, thrombocytopenia, gastrointestinal-related events (e.g., nausea, vomiting), and asthenia and fatigue. These side effects, many of which appear to be class effects of PARP inhibitors, are often self-limiting and can be managed with adequate interventions such as treatment interruption and\/or dose reduction and the use of supportive therapies. Supportive therapies may include blood transfusions for patients with anemia, prophylactic medications to prevent nausea and vomiting, or behavioral interventions to mitigate fatigue. Understanding and appropriate management of potential side effects associated with rucaparib may allow patients with ovarian cancer to continue to benefit from rucaparib treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0229","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T19:17:07Z","timestamp":1569957427000},"page":"e109-e119","source":"Crossref","is-referenced-by-count":15,"title":["Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10"],"prefix":"10.1093","volume":"25","author":[{"given":"Yvette","family":"Drew","sequence":"first","affiliation":[{"name":"Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca S.","family":"Kristeleit","sequence":"additional","affiliation":[{"name":"University College London Cancer Institute, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[{"name":"Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Ray-Coquard","sequence":"additional","affiliation":[{"name":"GINECO & Centre L\u00e9on B\u00e9rard and University Claude Bernard, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor Md.","family":"Haris","sequence":"additional","affiliation":[{"name":"Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"Swisher","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,10,1]]},"reference":[{"volume-title":"Global Cancer Observatory: Cancer Today","author":"Ferlay","key":"2021122510022870000_R1"},{"key":"2021122510022870000_R2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"2021122510022870000_R3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2021122510022870000_R4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.pgp.0000101080.35393.16","article-title":"The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin","volume":"23","author":"Seidman","year":"2004","journal-title":"Int J Gynecol Pathol"},{"volume-title":"Lynparza (olaparib) tablets [prescribing information]","year":"2018","key":"2021122510022870000_R5"},{"volume-title":"Rubraca (rucaparib) tablets [prescribing information]","year":"2018","key":"2021122510022870000_R6"},{"volume-title":"Rubraca (rucaparib) tablets [summary of product characteristics]","year":"2019","key":"2021122510022870000_R7"},{"volume-title":"Zejula (niraparib) capsules [prescribing information]","year":"2017","key":"2021122510022870000_R8"},{"volume-title":"Zejula (niraparib) capsules [summary of product information]","year":"2019","key":"2021122510022870000_R9"},{"volume-title":"Lynparza (olaparib) [summary of product information]","year":"2018","key":"2021122510022870000_R10"},{"key":"2021122510022870000_R11","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1158\/1535-7163.MCT-06-0552","article-title":"Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial","volume":"6","author":"Thomas","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"2021122510022870000_R12","doi-asserted-by":"crossref","first-page":"12629","DOI":"10.1073\/pnas.1007983107","article-title":"Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing","volume":"107","author":"Walsh","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122510022870000_R13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"The Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"2021122510022870000_R14","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.tibs.2012.06.007","article-title":"Links between genome integrity and BRCA1 tumor suppression","volume":"37","author":"Li","year":"2012","journal-title":"Trends Biochem Sci"},{"key":"2021122510022870000_R15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/bcr3670","article-title":"Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers","volume":"16","author":"Watkins","year":"2014","journal-title":"Breast Cancer Res"},{"key":"2021122510022870000_R16","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.dnarep.2007.02.006","article-title":"DNA double-strand break repair: From mechanistic understanding to cancer treatment","volume":"6","author":"Helleday","year":"2007","journal-title":"DNA Repair (Amst)"},{"key":"2021122510022870000_R17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"2021122510022870000_R18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S1097-2765(00)80202-6","article-title":"BRCA1 controls homology-directed DNA repair","volume":"4","author":"Moynahan","year":"1999","journal-title":"Mol Cell"},{"key":"2021122510022870000_R19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1097-2765(01)00174-5","article-title":"BRCA2 is required for homology-directed repair of chromosomal breaks","volume":"7","author":"Moynahan","year":"2001","journal-title":"Mol Cell"},{"key":"2021122510022870000_R20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","article-title":"Cancer susceptibility and the functions of BRCA1 and BRCA2","volume":"108","author":"Venkitaraman","year":"2002","journal-title":"Cell"},{"key":"2021122510022870000_R21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"key":"2021122510022870000_R22","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"2021122510022870000_R23","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"2021122510022870000_R24","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2021122510022870000_R25","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"2021122510022870000_R26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","article-title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2","volume":"147","author":"Oza","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2021122510022870000_R27","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1158\/1078-0432.CCR-16-2796","article-title":"A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1\/2-mutated ovarian carcinoma or other solid tumors","volume":"23","author":"Kristeleit","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2021122510022870000_R28","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): An international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021122510022870000_R29"},{"key":"2021122510022870000_R30"},{"key":"2021122510022870000_R31","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2004.04.132","article-title":"Recommended guidelines for the treatment of cancer treatment-induced diarrhea","volume":"22","author":"Benson","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122510022870000_R32"},{"key":"2021122510022870000_R33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/cts.12600","article-title":"Evaluation of drug\u2013drug interactions of rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp substrates in patients with an advanced solid tumor","volume":"12","author":"Xiao","year":"2019","journal-title":"Clin Transl Science"},{"key":"2021122510022870000_R34","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122510022870000_R35","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122510022870000_R36","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","article-title":"The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: A phase 1 dose-escalation trial","volume":"14","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol"},{"key":"2021122510022870000_R37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","article-title":"Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy","volume":"140","author":"Domchek","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2021122510022870000_R38","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122510022870000_R39","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/annonc\/mdw133","article-title":"Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1\/2 mutation: A multistudy analysis of response rates and safety","volume":"27","author":"Matulonis","year":"2016","journal-title":"Ann Oncol"},{"key":"2021122510022870000_R40","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021122510022870000_R41"},{"key":"2021122510022870000_R42","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/00498254.2016.1241449","article-title":"In vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib","volume":"47","author":"McCormick","year":"2017","journal-title":"Xenobiotica"},{"key":"2021122510022870000_R43","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1002\/jps.23737","article-title":"Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K)","volume":"102","author":"Kikuchi","year":"2013","journal-title":"J Pharm Sci"},{"key":"2021122510022870000_R44","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pds.1211","article-title":"Hy's law: Predicting serious hepatotoxicity","volume":"15","author":"Temple","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2021122510022870000_R45"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0229","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0229","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/1\/e109\/41919087\/oncolo_25_1_e109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/1\/e109\/41919087\/oncolo_25_1_e109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:04:08Z","timestamp":1640426648000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/1\/e109\/6443226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,10,1]]},"published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0229","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2020,1,1]]},"published":{"date-parts":[[2019,10,1]]}}}